Our new Cryptocurrency section has arrived! Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovartis N Ord Regulatory News (0QLR)

Share Price Information for Novartis N Ord (0QLR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 91.18
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 94.50
High: 91.77
Low: 90.79
Yest. Close: 91.18
0QLR Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.
Date   Source Headline
17th Sep 20196:15 amREUNovartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis
30th Aug 20196:15 amREUNovartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies
29th Jul 20196:00 amREUNovartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF)
18th Jul 20196:00 amREUNovartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased
1st Jul 20194:30 pmREUNovartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio
7th Jun 20196:00 amREUNovartis announces new leader of Pharmaceuticals Business Unit
26th May 201911:00 pmREUFDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
24th May 20195:41 pmREUAveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
24th May 20195:32 pmREUAveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
8th May 201911:20 pmREUNovartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care
24th Apr 20196:00 amREUNovartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded
26th Mar 201911:35 pmREUNovartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
22nd Mar 20196:00 amREUNovartis plans for Alcon spin-off on April 9, 2019
14th Mar 20196:15 amREUNovartis announces change in Sandoz leadership
25th Feb 201910:55 pmREUNovartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off
30th Jan 20193:17 pmREUNOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2018
30th Jan 20196:00 amREUNovartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018
18th Oct 20186:02 amREUNovartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms
18th Oct 20186:00 amREUNovartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth
29th Aug 20186:00 amREUAlcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma
23rd Aug 20186:15 amREUSOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation
14th Aug 20186:00 amREUNovartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer

Login to your account

Don't have an account? Click here to register.